22157.jpg
Psychedelic Therapeutics Clinical Trials Research Report 2024 Featuring Yale University, Johnson & Johnson, Shire Pharmaceuticals, Pfizer, Lykos, and UCB
13 sept. 2024 06h55 HE | Research and Markets
Dublin, Sept. 13, 2024 (GLOBE NEWSWIRE) -- The "Clinical Trials: Psychedelic Therapeutics" report has been added to ResearchAndMarkets.com's offering.This report provides a review of global...
TM-Logo-Navy.png
Novotech Announces MOU with Experienced Psychedelics Research Center at the 4th Annual Psychedelic Therapeutics and Drug Development Conference in Boston
22 mai 2024 20h11 HE | Novotech
Novotech Announces MOU with Experienced Psychedelics Research Center at the 4th Annual Psychedelic Therapeutics and Drug Development Conference in Boston
ibn_169.jpg
PsychedelicNewsWire Named Official Media Sponsor of the 4th Annual Psychedelic Therapeutics and Drug Development Conference
17 mai 2024 09h35 HE | InvestorBrandNetwork (IBN)
LOS ANGELES, May 17, 2024 (GLOBE NEWSWIRE) -- PsychedelicNewsWire (“PNW”), a specialized communications platform for the psychedelics sector and one of the 60+ brands powered by IBN...
ARROWHEAD logo.jpg
4th Annual Psychedelic Therapeutics and Drug Development Conference Scheduled for May 23-24 in Boston, MA
16 mai 2024 09h35 HE | Arrowhead SciTech Conferences & Events
NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- via PsychedelicNewsWire (“PNW”) — Following three impactful conferences, Arrowhead Sci-Tech Conferences and Events (“Arrowhead”) is pleased to announce the...
mydecine.jpg
Mydecine Provides Q4 2023 Business Update
26 oct. 2023 02h00 HE | Mydecine Innovations Group Inc.
Mydecine is pleased to address its shareholders and provide a general update on the company's progress.
InsightAce.jpg
Psychedelic Therapeutics Market Grow at a CAGR 14.92 % from 2023 to 2031 | Exclusive InsightAce Report
27 juin 2023 10h20 HE | InsightAce Analytic Pvt. LTd.
Jersey City, NJ, June 27, 2023 (GLOBE NEWSWIRE) -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Psychedelic Therapeutics Market Size, Share &...
Cybin LOGO.png
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leads Out in Psychedelic-Based Therapeutics Space
07 mars 2022 08h30 HE | Cybin Inc.
NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) announces the availability of a broadcast titled, “Psychedelic Therapies Offer Hope for...
Cybin LOGO.png
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Unleashing Power of Psychedelics
03 mars 2022 08h30 HE | Cybin Inc.
NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- via InvestorWire — Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one...
SILO_LOGO_A.png
Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer’s Disease
27 oct. 2021 08h15 HE | SILO PHARMA INC.
Englewood Cliffs, NJ, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
Cybin LOGO.png
Cybin Inc. (NEO: CYBN) at Forefront of Psychedelic Revolution
26 mars 2021 08h30 HE | Cybin Inc.
NEW YORK, March 26, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Cybin Inc. (NEO: CYBN) announces the availability of a broadcast titled, “Science Drives Surging Interest in Psychedelic...